RE:RE:RE:History RepeatsAnother good post from Quentin.
I too am unhappy with Bracelet. They either chose the wrong CPI or the wrong trial design to show efficacy with Avelumab. And we're out of time now to backtrack.
My own opinion is that ONC will never run a Phase III with mbc. It's pancreatic or bust for ONC now. And that's why I'm quite disturbed that we have not executed any definitive agreements to get that Phase III going. Personally I think the company should take any partnership (or, if we were lucky, a buyout) on offer. Shareholders like myself are tired of diluation and tired of waiting. And frankly, management has not shown any great skill in designing or running trials.
If this really can help cancer patients (and I think it might), then let's get into the hands of someone who can get it across the finish line.